Efficacy and safety of perampanel in epilepsy: A systematic review and meta-analysis of randomised controlled trials

Published:September 28, 2022DOI:


      • This systematic review reports significant reduction in seizures and a potential dose-based increase in discontinuations due to TEAE.
      • When compared with placebo, both 8 mg and 12 mg doses of perampanel showed similar efficacy in seizure control.
      • A higher risk of treatment discontinuation was found among 12 mg users than among 8 mg users.
      • The most reported TEAEs were non-threatening, with the potential possibility of rare but serious adverse psychological outcomes.
      • Further comparative effectiveness trials – as well as longitudinal follow-up observational studies – are needed to decide on the optimal doses for epilepsy management with perampanel.



      Perampanel a third-generation antiseizure medication, belongs to a new promising class of drugs called AMPA receptor antagonists, approved to treat focal-onset seizures with or without focal to bilateral tonic clonic seizures and primary generalized tonic-clonic seizures.


      This review included RCTs on patients with epilepsy exposed to perampanel compared with placebo, or one or more pre-existing antiseizure medications. Four databases and two clinical trial registries were searched from inception to July 2021. Included outcomes were 50% responder rate, seizure-free rate, discontinuation due to treatment-emergent adverse events (TEAE)s, having any TEAEs, and most reported TEAEs. Cochrane risk of bias tool was used to assess the internal validity of the included RCTs.


      From 2211 retrieved citations, eight RCTs were included in the meta-analysis. Fifty-percent responder and seizure freedom rates were significantly higher in patients receiving perampanel when compared to placebo (RR 1.57, 95 % CI 1.35 to 1.82, I2 15% and RR 2.79, 95% CI 1.58 to 4.93, I2 7%, respectively). The 50% responder rates for 8mg and 12 mg, when compared to placebo, were similar. The most-reported TEAEs were dizziness and somnolence with <1% reporting serious psychological outcomes.


      This systematic review reports significant reduction in seizures and a potential dose-based increase in discontinuations due to TEAE. The most-reported TEAEs were non-threatening, with the possibility of rare but serious adverse psychological outcomes. Further independent RCTs studying the most efficient dose for efficacy and safety are needed.



      ASMs (Antiseizure medications), IPA (International pharmaceutical abstracts), CINAHL (Cumulative index of nursing and allied health literature, Cochrane risk-of-bias tool for randomised trials (RoB 2)), PRISMA (Preferred reporting items for systematic reviews and meta-analyses), RCT (Randomised controlled trials), TEAEs (Treatment emergent adverse events), WHO (World Health Organization), ICTRP (International Clinical Trials Registry Platform and RR: Risk ratios)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Seizure - European Journal of Epilepsy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. WHO. Epilepsy: A Public Health Imperative.; 2019.

      2. National Institute of Neurological Disorders and Stroke. The Epilepsies and Seizures. 2018.

        • Mula M
        • Sander JW.
        Psychosocial aspects of epilepsy: a wider approach.
        BJPsych Open. 2016; 2: 270-274
      3. Nguyen V V, Baca CB, Chen JJ, Rogers SJ. Chapter 56 : Epilepsy. 2021.

        • Hanada T
        • Hashizume Y
        • Tokuhara N
        • et al.
        Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy.
        Epilepsia. 2011; 52: 1331-1340
        • FDA
        Full Prescribing Information Perampanel.
        Clin Trials. 2012;
        • Mahajan SS
        • Prakash A
        • Sarma P
        • Niraj N
        • Bhattacharyya A
        • Medhi B.
        Efficacy, tolerability and safety of perampanel in population with pharmacoresistant focal seizures: A systematic review and meta-analysis.
        Epilepsy Res. 2022; 182106895
        • Hsu WWQ
        • Sing CW
        • He Y
        • Worsley AJ
        • Wong ICK
        • Chan EW.
        Systematic review and meta-analysis of the efficacy and safety of perampanel in the treatment of partial-onset epilepsy.
        CNS Drugs. 2013; 27: 817-827
        • French JA
        • Krauss GL
        • Wechsler RT
        • et al.
        Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy.
        Neurology. 2015; 85: 950-957
        • Nishida T
        • Lee SK
        • Inoue Y
        • Saeki K
        • Ishikawa K
        • Kaneko S.
        Adjunctive perampanel in partial-onset seizures: Asia-Pacific, randomized phase III study.
        Acta Neurol Scand. 2018; 137: 392-399
        • Lagae L
        • Villanueva V
        • Meador KJ
        • et al.
        Adjunctive perampanel in adolescents with inadequately controlled partial-onset seizures: A randomized study evaluating behavior, efficacy, and safety.
        Epilepsia. 2016; 57: 1120-1129
        • Page MJ
        • McKenzie JE
        • Bossuyt PM
        • et al.
        PRISMA 2020 Checklist.
        BMJ. 2021; 372: 2020-2021
        • Ouzzani M
        • Hammady H
        • Fedorowicz Z
        • Elmagarmid A.
        Rayyan-a web and mobile app for systematic reviews.
        Syst Rev. 2016; 5: 1-11
        • Page MJ
        • McKenzie JE
        • Bossuyt PM
        • et al.
        The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.
        BMJ. 2021; 372: n71
      4. RevMan User guide. Welcome to RevMan 5 . 4. 2020;4(May).

        • Higgins JPT
        • Thomas J
        • Chandler J
        • Cumpston M
        • Li T
        • Page MJ WV
        Cochrane Handbook for Systematic Reviews of Interventions Version 6.2. 2021; (editors)
        • Krauss GL
        • Bar M
        • Biton V
        • et al.
        Tolerability and safety of perampanel: Two randomized dose-escalation studies.
        Acta Neurol Scand. 2012; 125: 8-15
        • French JA
        • Krauss GL
        • Biton V
        • et al.
        Adjunctive perampanel for refractory partial-onset seizures.
        Neurology. 2012; 79 (LP - 596): 589
        • Krauss GL
        • Serratosa JM
        • Villanueva V
        • et al.
        Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures.
        Neurology. 2012; 78: 1408-1415
        • French JA
        • Krauss GL
        • Steinhoff BJ
        • et al.
        Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: Results of randomized global phase III study 305.
        Epilepsia. 2013; 54: 117-125
        • FDA
        Perampanel FDA 2018.
        Fda. 2018;
        • Meador KJ
        • Yang H
        • Piña-Garza JE
        • Laurenza A
        • Kumar D
        • Wesnes KA.
        Cognitive effects of adjunctive perampanel for partial-onset seizures: A randomized trial.
        Epilepsia. 2016; 57: 243-251
        • Rugg-Gunn F.
        Adverse effects and safety profile of perampanel: a review of pooled data.
        Epilepsia. 2014; 55 (Suppl): 13-15
        • Villanueva V
        • Garcés M
        • López-González FJ
        • et al.
        Safety, efficacy and outcome-related factors of perampanel over 12 months in a real-world setting: The FYDATA study.
        Epilepsy Res. 2016; 126: 201-210
        • Rohracher A
        • Kalss G
        • Leitinger M
        • et al.
        Two-year real-world experience with perampanel in patients with refractory focal epilepsy: Austrian data.
        Ther Adv Neurol Disord. 2016; 9: 445-453
        • Morano A
        • Fattouch J
        • Albini M
        • et al.
        Perampanel as adjunctive therapy in highly refractory epilepsies: Real-world data from an Italian tertiary care epilepsy centre.
        J Neurol Sci. 2018; 390: 67-74
        • Zaccara G
        • Gangemi PF
        • Cincotta M.
        Central nervous system adverse effects of new antiepileptic drugs. A meta-analysis of placebo-controlled studies.
        Seizure. 2008; 17: 405-421
        • Martyn-St James M
        • Glanville J
        • McCool R
        • et al.
        The efficacy and safety of retigabine and other adjunctive treatments for refractory partial epilepsy: A systematic review and indirect comparison.
        Seizure. 2012; 21: 665-678
        • Steinhoff BJ
        • Bacher M
        • Bast T
        • et al.
        First clinical experiences with perampanel-The Kork experience in 74 patients.
        Epilepsia. 2014; 55 (SUPPL): 16-18
        • Morsi RZ
        • Katz JA.
        Zombielike” Aggression in Perampanel Overdose.
        Cureus. 2021; 13: 11-14